Filing Flows › Comparisons › ENTX vs VIVS
Entera Bio vs VivoSim Labs: ENTX and VIVS compared
Entera Bio is the larger company: $42K of revenue in its latest quarter (Q1 2025) against $18K for VivoSim Labs (Q1 FY27).
Where the money goes: ENTX and VIVS
Entera Bio (ENTX) · Q1 2025
Entera Bio, Q1 2025: revenue $42K, net loss $2.6M, operating cash flow −$1.4M. The chart follows the revenue to costs, profit and cash.
VivoSim Labs (VIVS) · Q1 FY27
VivoSim Labs, Q1 FY27: revenue $18K (-51% year over year), net loss $1.3M, operating cash flow −$3.2M. The chart follows the revenue to costs, profit and cash.
| Entera Bio (ENTX) | VivoSim Labs (VIVS) | |
|---|---|---|
| Latest quarter | Q1 2025 | Q1 FY27 |
| Revenue | $42K | $18K |
| Revenue growth, Y/Y | — | -51% |
| Operating margin | n/m | n/m |
| Net earnings | −$2.6M | −$1.3M |
| Operating cash flow | −$1.4M | −$3.2M |
Questions
Which is bigger, Entera Bio or VivoSim Labs?
Entera Bio is the larger company: $42K of revenue in its latest quarter (Q1 2025) against $18K for VivoSim Labs (Q1 FY27).
More: Entera Bio earnings · how Entera Bio makes money · VivoSim Labs earnings · how VivoSim Labs makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 9, 2025; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.